MNTA’s $5M milestone for FDA approval of generic Lovenox is separate from the $163M of remaining potential milestones from the 2006 NVS-MNTA collaboration. The $163M pertains to Lovenox in the EU, specifically, and to Copaxone.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.